The early course of affective and cognitive symptoms in de novo patients with Parkinson's disease

Journal of Neurology

Volumn 261, Issue 6, 2014, Pages 1126-1132

  Spalletta, Gianfranco ^a   Robinson, Robert G ^b   Cravello, Luca ^a   Pontieri, Francesco E ^a,c   Pierantozzi, Mariangela ^d   Stefani, Alessandro ^d   Long, Jeffrey D ^b,e   Caltagirone, Carlo ^a,d   Assogna, Francesca ^a  

^a IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^b UNIVERSITY OF IOWA   (United States)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d UNIVERSITY OF ROME TOR VERGATA   (Italy)

^e UNIVERSITY OF IOWA   (United States)

Author keywords

Depression; Memory; Neuropsychology; Parkinson's disease

Indexed keywords

ANTIDEPRESSANT AGENT; ANTIPARKINSON AGENT; BENZODIAZEPINE; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA;

ADULT; APATHY; ARTICLE; CLINICAL ARTICLE; COGNITIVE DEFECT; DEPRESSION; DISEASE ASSOCIATION; DISEASE COURSE; EDUCATIONAL STATUS; EMOTIONAL DISORDER; EPISODIC MEMORY; FEMALE; FOLLOW UP; GENERALIZED ANXIETY DISORDER; HUMAN; LONG TERM MEMORY; MALE; MOTOR DYSFUNCTION; NEUROLOGIC EXAMINATION; NEUROPSYCHOLOGICAL TEST; ONSET AGE; PARKINSON DISEASE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SEX RATIO; SHORT TERM MEMORY; VERBAL MEMORY; VISUAL MEMORY; AGE; AGED; COGNITION DISORDERS; COMPLICATION; LONGITUDINAL STUDY; MENTAL HEALTH; MIDDLE AGED; MOOD DISORDERS;

AGE FACTORS; AGED; ANTIPARKINSON AGENTS; COGNITION DISORDERS; DISEASE PROGRESSION; EDUCATIONAL STATUS; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MENTAL STATUS SCHEDULE; MIDDLE AGED; MOOD DISORDERS; NEUROLOGIC EXAMINATION; NEUROPSYCHOLOGICAL TESTS; PARKINSON DISEASE;

EID: 84903649211     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-014-7327-6     Document Type: Article

References (40)

1. Kehagia AA, Barker RA, Robbins TW (2010) Neuropsychological and clinical heterogeneity of cognitive impairment and dementia in patients with Parkinson's disease. Lancet Neurol 9:1200-1213
2. Aarsland D, Brønnick K, Larsen JP, Tysnes OB, Alves G (2009) Cognitive impairment in incident, untreated Parkinson disease: the Norwegian ParkWest study. Neurology 72:1121-1126
3. Miah IP, Olde Dubbelink KT, Stoffers D, Deijen JB, Berendse HW (2012) Early-stage cognitive impairment in Parkinson's disease and the influence of dopamine replacement therapy. Eur J Neurol 19:510-516
4. Pagni C, Frosini D, Ceravolo R, Giunti G, Unti E, Poletti M, McClintock SM, Murri L, Bonuccelli U, Tognoni G (2011) Event-based prospective memory in newly diagnosed, drug-naive Parkinson's disease patients. J Int Neuropsychol Soc 17:1158-1162
5. Ceravolo R, Frosini D, Poletti M, Kiferle L, Pagni C, Mazzucchi S, Volterrani D, Bonuccelli U (2013) Mild affective symptoms in de novo Parkinson's disease patients: relationship with dopaminergic dysfunction. Eur J Neurol 20:480-485
6. Erro R, Santangelo G, Picillo M, Vitale C, Amboni M, Longo K, Costagliola A, Pellecchia MT, Allocca R, De Rosa A, De Michele G, Santoro L, Barone P (2012) Link between non-motor symptoms and cognitive dysfunctions in de novo, drug-naive PD patients. J Neurol 259:1808-1813
7. Kim HJ, Park SY, Cho YJ, Hong KS, Cho JY, Seo SY, Lee DH, Jeon BS (2009) Nonmotor symptoms in de novo Parkinson disease before and after dopaminergic treatment. J Neurol Sci 287:200-204
8. Poletti M, Lucetti C, Del Dotto P, Berti C, Logi C, Bonuccelli U (2012) Relationship between neuropsychiatric symptoms and cognitive performance in de novo Parkinson's disease. J Neuropsychiatry Clin Neurosci 24:E22-E23
9. Costa A, Peppe A, Dell'Agnello G, Caltagirone C, Carlesimo GA (2009) Dopamine and cognitive functioning in de novo subjects with Parkinson's disease: effects of pramipexole and pergolide on working memory. Neuropsychologia 47:1374-1381
10. Kulisevsky J (2000) Role of dopamine in learning and memory: implications for the treatment of cognitive dysfunction in patients with Parkinson's disease. Drugs Aging 16:365-379
11. Kulisevsky J, Garcia-Sanchez C, Berthier ML, Barbanoj M, Pascual-Sedano B, Gironell A, Estevez-Gonzalez A (2000) Chronic effects of dopaminergic replacement on cognitive function in Parkinson's disease: a two-year follow-up study of previously untreated patients. Mov Disord 15:613-626
12. Marini P, Ramat S, Ginestroni A, Paganini M (2003) Deficit of short-term memory in newly diagnosed untreated parkinsonian patients: reversal after L-dopa therapy. Neurol Sci 24:184-185
13. Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992) Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55:181-184
14. Folstein MF, Folstein SE, McHugh PR (1975) "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189-198
15. Emre M, Aarsland D, Brown R, Burn DJ, Duyckaerts C, Mizuno Y, Broe GA, Cummings J, Dickson DW, Gauthier S, Goldman J, Goetz C, Korczyn A, Lees A, Levy R, Litvan I, McKeith I, Olanow W, Poewe W, Quinn N, Sampaio C, Tolosa E, Dubois B (2007) Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord 22:1689-1707
16. APA (2000) Diagnostic and Statistical Manual of Mental Disorders. 4th eds, text revision (DSM-IV-TR). Washington, DC
17. de Leeuw FE, de Groot JC, Achten E, Oudkerk M, Ramos LM, Heijboer R, Hofman A, Jolles J, van Gijn J, Breteler MM (2001) Prevalence of cerebral white matter lesions in elderly people: a population based magnetic resonance imaging study. The Rotterdam Scan Study. J Neurol Neurosurg Psychiatry 70:9-14
18. Horstink M, Tolosa E, Bonuccelli U, Deuschl G, Friedman A, Kanovsky P, Larsen JP, Lees A, Oertel W, Poewe W, Rascol O, Sampaio C (2006) Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies and the Movement Disorder Society-European Section. Part I: early (uncomplicated) Parkinson's disease. Eur J Neurol 13:1170-1185
19. Fahn S, Elton RL, Members of the UPDRS Development Committee (1987) Unified Parkinson's Disease Rating Scale. In: Fahn S, Calne D, Goldstein M (eds) Recent Developments in Parkinson's Disease. MacMillan Health Care Information, Florham Park, pp 153-304
20. First MB, Spitzer RL, Gibbon M, Williams JBW (2002) Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Non Patient Edition (SCID-I/NP). New York State Psychiatric Institute, New York
21. Beck AT, Steer RA (1987) Beck Depression Inventory Manual. San Antonio, TX
22. Hamilton M (1959) The assessment of anxiety states by rating. Br J Med Psychol 32:50-55
23. Snaith RP, Hamilton M, Morley S, Humayan A, Hargreaves D, Trigwell P (1995) A scale for the assessment of hedonic tone the Snaith-Hamilton Pleasure Scale. Br J Psychiatry 167:99-103
24. Starkstein SE, Mayberg HS, Preziosi TJ, Andrezejewski P, Leiguarda R, Robinson RG (1992) Reliability, validity, and clinical correlates of apathy in Parkinson's disease. J Neuropsychiatry Clin Neurosci 4:134-139
25. Starkstein SE, Merello M, Jorge R, Brockman S, Bruce D, Power B (2009) The syndromal validity and nosological position of apathy in Parkinson's disease. Mov Disord 24:1211-1216
26. Schrag A, Jahanshahi M, Quinn N (2000) How does Parkinson's disease affect quality of life? A comparison with quality of life in the general population. Mov Disord 15:1112-1118
27. Carlesimo GA, Caltagirone C, Gainotti G (1996) The Mental Deterioration Battery: normative data, diagnostic reliability and qualitative analyses of cognitive impairment. The Group for the Standardization of the Mental Deterioration Battery. Eur Neurol 36:378-384
28. Pinheiro JC, Bates DM (2000) Mixed-effects models in S and S-PLUS. Springer, New York
29. Pinheiro JC, Bates DM, DebRoy S, Sarkar D, Team RDC (2013) NLME: linear and nonlinear mixed effects models. R package version 3.1-111. Computer manual
30. R Core Team (2013) R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. www.R-project.org
31. Lemke MR, Brecht HM, Koester J, Reichmann H (2006) Effects of the dopamine agonist pramipexole on depression, anhedonia and motor functioning in Parkinson's disease. J Neurol Sci 248:266-270
32. Vu TC, Nutt JG, Holford NH (2012) Progression of motor and nonmotor features of Parkinson's disease and their response to treatment. Br J Clin Pharmacol 74:267-283
33. Chaudhuri KR, Schapira AH (2009) Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment. Lancet Neurol 8:464-474
34. Costa FH, Rosso AL, Maultasch H, Nicaretta DH, Vincent MB (2012) Depression in Parkinson's disease: diagnosis and treatment. Arq Neuropsiquiatr 70:617-620
35. Gallagher DA, Schrag A (2008) Impact of newer pharmacological treatments on quality of life in patients with Parkinson's disease. CNS Drugs 22:563-586
36. Mayberg HS (1994) Frontal lobe dysfunction in secondary depression. J Neuropsychiatry Clin Neurosci 6:428-442
37. Starkstein SE, Preziosi TJ, Bolduc PL, Robinson RG (1990) Depression in Parkinson's disease. J Nerv Ment Dis 178:27-31
38. Witjas T, Kaphan E, Azulay JP, Blin O, Ceccaldi M, Pouget J, Poncet M, Cherif AA (2002) Nonmotor fluctuations in Parkinson's disease: frequent and disabling. Neurology 59:408-413
39. Erro R, Picillo M, Vitale C, Amboni M, Moccia M, Longo K, Cozzolino A, Giordano F, De Rosa A, De Michele G, Pellecchia MT, Barone P (2013) Non-motor symptoms in early Parkinson's disease: a 2-year follow-up study on previously untreated patients. J Neurol Neurosurg Psychiatry 84:14-17
40. Cools R, Barker RA, Sahakian BJ, Robbins TW (2003) L-Dopa medication remediates cognitive inflexibility, but increases impulsivity in patients with Parkinson's disease. Neuropsychologia 41:1431-1441